Results 31 to 40 of about 1,721 (143)

Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy [PDF]

Signal Transduction and Targeted Therapy
Calcific aortic valve disease (CAVD) is a prevalent age-related valvulopathy characterized by high morbidity and mortality. CAVD pathogenesis involves maladaptive differentiation of valvular interstitial cells (VICs) into profibrotic and osteogenic ...
Yan Wang, Fei Xu, Chengxiang Song, Xi Wang, Hao Zhou, Tianyi Qu, Hongde Li, Qiang Luo, Wenhua Lei, Yue Yin, Fangyang Huang, Mao Chen   +11 more
doaj   +2 more sources

ANMCO Position Paper: Vericiguat use in heart failure: From evidence to place in therapy [Position paper ANMCO: Impiego di vericiguat nello scompenso cardiaco: dalle evidenze al posizionamento terapeutico] [PDF]

, 2023
In the growing therapeutic armamentarium for heart failure management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for heart failure. Indeed, vericiguat does not inhibit
Intravaia R. C. M., Gulizia M. M., Aquilani S., Cipriani M., Gabrielli D., Oliva F., Matteucci A., Navazio A., Valente S., Aimo A., Di Fusco S. A., De Luca L., Alonzo A., Colivicchi F.   +13 more
core   +2 more sources

Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics

AAPS Open, 2022
Objective This article describes in vitro and in vivo studies that aimed to further characterize the biopharmaceutical properties and pharmacokinetic (PK) profile of vericiguat and to guide dosing recommendations. Methods Five open-label, phase I studies
Corina Becker, Michael Boettcher, Uwe Muenster, Stephanie Loewen, Maximilian Lobmeyer, Wolfgang Mueck   +5 more
doaj   +1 more source

Impact of vericiguat on baroreflex-mediated sympathetic circulatory regulation: An open-loop analysis.

PLoS ONE, 2023
AimsTo quantify in vivo the effects of the soluble guanylate cyclase (sGC) stimulator, vericiguat, on autonomic cardiovascular regulation in comparison with the nitric oxide (NO) donor, sodium nitroprusside.MethodsIn anesthetized Wistar-Kyoto rats ...
Aimi Yokoi, Toru Kawada, Shohei Yokota, Midori Kakuuchi, Hiroki Matsushita, Akitsugu Nishiura, Meihua Li, Kazunori Uemura, Joe Alexander, Ryou Tanaka, Keita Saku   +10 more
doaj   +1 more source

Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science

Clinical and Translational Science, 2023
Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF).
Maria E. Trujillo, Surya Ayalasomayajula, Robert O. Blaustein, Ferdous Gheyas   +3 more
doaj   +1 more source

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction [PDF]

, 2020
BACKGROUND The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS In
Lam, Carolyn S P, Lam, Carolyn S. P., Anstrom, Kevin, J, Patel, Mahesh J., Armstrong, Paul W., Christopher M, Armstrong, Paul W, O'Connor, Christopher M., Hernandez, Adrian F, Jia, Gang, Hernandez, Adrian F., Voors, Adriaan A., O'Connor, Voors, Adriaan A, Patel, Mahesh, J, Mcnulty, Steven, E, Butler, Javed, Armstrong, Paul, W, McNulty, Steven E., Ezekowitz, Justin, Patel, Mahesh J, Koglin, Joerg, O'Connor, Christopher M, Nodari S, Hernandez, Adrian, F, Ponikowski, Piotr, Cohen-Solal, Alain, Roessig, Lothar, VICTORIA Study Group, Lam, Carolyn, S P, Voors, Adriaan, A, Anstrom, Kevin J, Anstrom, Kevin J., McNulty, Steven E, Pol, Tymon,, Pieske, Burkert, O’connor, Christopher, M   +36 more
core   +2 more sources

Vericiguat protects against cardiac damage in a pig model of ischemia/reperfusion.

PLoS ONE, 2023
BackgroundThe purpose of this research was to verify that vericiguat, a soluble guanylate cyclase (sGC) stimulator, reduces myocardial ischemic reperfusion injury (MIRI), and to learn how this reduction happens.Methods and resultsTo develop an ischaemia ...
Weida Zhu, Yue Ben, Yang Shen, Wenbing Liu   +3 more
doaj   +1 more source

The Evolving Role of Vericiguat in Patients With Chronic Heart Failure [PDF]

, 2023
Heart failure (HF) is a chronic and progressive clinical disorder characterized by an inability to pump sufficient blood to meet metabolic demands. It poses a substantial global healthcare burden, leading to high morbidity, mortality, and economic impact.
Sinnathamby, Evan S, Singh, Naina, Flanagan, Chelsi J, Spillers, Noah J, Varrassi, Giustino, Ahmadzadeh, Shahab, Kaye, Alan D, Dies, Ross M, Jackson, Corrie N, Potharaju, Pooja, Shekoohi, Sahar   +10 more
core   +1 more source

Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats

, 2022
Vericiguat is a soluble guanylate cyclase stimulator. The pharmacokinetics, absorption, metabolism, and excretion properties of vericiguat in rats and dogs and the distribution in rats are reported.
Wiebke Janssen (1788330), Steffen Sandmann (12912754), Dieter Lang (4100539), Armin Kern (4100554), Ulf Bütehorn (12912748), Thomas Schwarz (382155), Frank Hucke (12912757), Michael Gerisch (2706262), Wolfram Steinke (12912751)   +8 more
core   +1 more source

Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat-A Narrative Review. [PDF]

J Clin Med
Heart failure (HF) remains a major global health burden despite substantial therapeutic advances. Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, represents a distinct pharmacological strategy targeting impaired nitric oxide–sGC–cyclic ...
Kubica J, Kubica A, Gajda R, Laskowska E, Umińska JM, Ratajczak J, Niezgoda P, Mrzywka N, Szarpak Ł, Navarese EP.   +9 more
europepmc   +2 more sources